Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.20.1
Consolidated Statements of Cash Flows
12 Months Ended
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Operating activities    
Net loss $ (16,072,547) $ (40,052,810)
Adjustments to reconcile net loss used in operating activities:    
Depreciation and amortization 3,883,567 4,554,963
Impairment of intangible assets 1,449,121 1,861,562
Stock-based compensation, excluding amount included within gain on sale of Pediatric Portfolio 2,532,257 2,431,063
Acquired in-process research and development 0 18,723,952
Deferred taxes 16,743 (16,745)
Amortization of inventory fair value adjustment associated with acquisition of TRx and Avadel pediatric products 107,271 300,573
Non-cash interest expense 0 302,882
Gain on Aytu Divestiture (7,964,924) 0
Change in fair value of Investment in Aytu (53,932) 0
Change in fair value of contingent consideration liability (1,009,169) 58,366
Change in fair value of warrant liability and unit purchase option liability 3,888 (25,010)
Changes in assets and liabilities, net of Aytu Divestiture:    
Accounts receivable, net 1,658,333 (222,530)
Other receivables (excluding Aevi Loan) 5,120,247 (2,277,255)
Inventory, net 532,947 (311,199)
Prepaid expenses and other assets (917,016) (241,641)
Escrowed cash receivable 0 3,752,390
Accounts payable 1,019,358 82,451
Income taxes payable (1,480,587) (226,890)
Accrued expenses and other liabilities (6,835,395) 7,792,259
License obligations (1,250,000) 0
Lease liability, net 125,506  
Other long term liabilities 0 385,517
Net cash used in operating activities (19,134,332) (3,128,102)
Investing activities    
Net cash received from Aytu Divestiture 3,958,412 0
Loan to Aevi (4,139,401)  
Avadel pediatric products acquisition 0 (1)
Net cash acquired from acquisition of Ichorion Therapeutics, Inc. 0 1,429,877
Purchase of property and equipment (262,013) (564,415)
Net cash (used in) provided by investing activities (443,002) 865,461
Financing activities    
Proceeds from exercise of stock options and warrants 836,188 1,083,953
Proceeds from shares purchased through employee stock purchase plan 210,777 72,236
Restricted Stock Units withheld for taxes (33,959)  
Proceeds from sale of shares pursuant to common stock private placement, net 3,708,602 3,857,106
Proceeds from sale of shares of common stock in underwritten public offering, net of offering costs 8,975,960  
Proceeds from issuance of Series B convertible preferred stock upon warrant exercise, net 0 5,685,038
Payment of contingent consideration (881,932) (294,435)
Payment of long-term debt (256,140) 0
Net cash provided by financing activities 12,559,496 10,403,898
(Decrease) increase in cash and cash equivalents (7,017,838) 8,141,257
Cash, cash equivalents, and restricted cash at beginning of period 10,746,756 2,605,499
Cash, cash equivalents, and restricted cash at end of period 3,728,918 10,746,756
Supplemental disclosures of cash flow information    
Cash paid for interest 1,050,000 525,000
Cash paid for taxes 1,803,665 354,000
Supplemental disclosures of non-cash investing and financing activities    
Leased asset obtained in exchange for new operating lease liability 743,025  
Debt assumed in Avadel Pediatric Products acquisition 0 (15,075,000)
Cash and cash equivalents 3,609,438 10,646,301
Restricted cash, current portion 17,535 18,730
Restricted cash, net of current portion $ 101,945 $ 81,725